1. Home
  2. IAUX vs DMRA Comparison

IAUX vs DMRA Comparison

Compare IAUX & DMRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo i-80 Gold Corp.

IAUX

i-80 Gold Corp.

HOLD

Current Price

$1.54

Market Cap

1.5B

Sector

N/A

ML Signal

HOLD

DMRA

Damora Therapeutics Inc. Common Stock

N/A

Current Price

$24.03

Market Cap

1.6B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
IAUX
DMRA
Founded
2020
2011
Country
United States
United States
Employees
N/A
7
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.5B
1.6B
IPO Year
2021
2020

Fundamental Metrics

Financial Performance
Metric
IAUX
DMRA
Price
$1.54
$24.03
Analyst Decision
Buy
Buy
Analyst Count
1
2
Target Price
$1.50
$43.00
AVG Volume (30 Days)
11.9M
284.6K
Earning Date
05-12-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
11.76
N/A
EPS
N/A
N/A
Revenue
$95,193,000.00
N/A
Revenue This Year
$132.25
N/A
Revenue Next Year
$89.76
N/A
P/E Ratio
N/A
N/A
Revenue Growth
89.12
N/A
52 Week Low
$0.49
$16.50
52 Week High
$2.24
$28.76

Technical Indicators

Market Signals
Indicator
IAUX
DMRA
Relative Strength Index (RSI) 47.48 47.61
Support Level $1.44 $23.64
Resistance Level $1.95 $28.00
Average True Range (ATR) 0.07 1.83
MACD 0.01 -0.16
Stochastic Oscillator 42.05 50.60

Price Performance

Historical Comparison
IAUX
DMRA

About IAUX i-80 Gold Corp.

i-80 Gold Corp is a well-financed gold and silver producer engaged in the exploration, development, and production of gold, silver, and poly-metallic deposits. The Company's principal assets include the Ruby Hill Mine, Lone Tree Mine, Granite Creek Mine, and McCoy-Cove Project.

About DMRA Damora Therapeutics Inc. Common Stock

Damora Therapeutics Inc is a biotechnology company that aims to fundamentally redefine care for people with hematologic disorders. The group is advancing a new generation of biologics to treat mutant calreticulin-driven myeloproliferative neoplasms, including essential thrombocythemia and myelofibrosis, where there is cruicial medical need for disease-modifying treatments. Its goal is to rapidly bring forward optimized therapies with broad mutation coverage and exceptional convenience to dramatically improve patient outcomes. The group's pipeline products are DMR-001, DMR-002, DMR-003, and GB3226.

Share on Social Networks: